AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20363999
Drug: CO(2) therapy
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO(2) therapy in addition to routine methods (surgical and/or chemical debridement, advanced dressings)
Trial: 10732656
Drug: Venlafaxine 37.5
RxNorm normalized name: venlafaxine 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 37.5 mg b.i.d. (increased to 75 mg b.i.d. from day 15)
Trial: 10732656
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg once daily (remained at 50 mg b.i.d. from day 15)
Trial: 8887985
Drug: Placebo (1/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1/4 strength preparation of an amino acid mixture)
Trial: 3964710
Drug: Diltiazem and
RxNorm normalized name: Diltiazem and enalapril only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem and propranolol (120 mg diltiazem and 160 mg propranolol)
Trial: 31765046
Drug: elbasvir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elbasvir (50 mg)/grazoprevir (100 mg) for 8 weeks
Trial: 31765046
Drug: elbasvir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elbasvir (50 mg)/grazoprevir (100 mg) for 12 weeks
Trial: 31765046
Drug: elbasvir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elbasvir (50 mg)/grazoprevir (100 mg) for 12 weeks (treatment-experienced)
Trial: 31675351
Drug: Corticosteroid (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (1 mL methylprednisolone 40 mg/mL) + local anaesthetic (1 mL bupivacaine 5 mg/mL)
Trial: 23756080
Drug: 1-second benzocaine
RxNorm normalized name: benzocaine 0.1 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-second benzocaine spray before upper endoscopy
Trial: 23756080
Drug: No spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No spray (control group)
Trial: 21629111
Drug: Topical negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical negative pressure therapy
Trial: 21629111
Drug: Conventional dressing
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dressing therapy with sodium hypochlorite
Trial: 19793724
Drug: Intravenous diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diamorphine (0.1 mg/kg)
Trial: 16966534
Drug: Rivastigmine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (3 to 6 mg/day)
Trial: 9701294
Drug: Hydrocodone-acetaminophen (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone-acetaminophen (5 mg hydrocodone with 500 mg acetaminophen)
Trial: 2597854
Drug: Short educational
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short educational programme or routine treatment (Control)
Trial: 30281141
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser treatment followed by topical application of sodium stibogluconate
Trial: 30281141
Drug: Intralesional injections
RxNorm normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injections of sodium stibogluconate
Trial: 21447654
Drug: Tyramine infusion
RxNorm normalized name: tyramine
DrugBank: Tyramine (DB08841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyramine infusion during exercise
Trial: 21447654
Drug: Combined ATP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined ATP and tyramine infusions
Trial: 18331374
Drug: Carbohydrate-rich drink
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-rich drink (400 ml, 12.5%) with paracetamol 1.5 g
Trial: 11410122
Drug: Adrenomedullin (AM)
RxNorm normalized name: Adrenomedullin
DrugBank: Adrenomedullin (DB19102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenomedullin (AM) infusion (4 pmol.min(‐1).kg(‐1))
Trial: 9390695
Drug: New antiepileptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antiepileptic drugs and nonpharmacologic treatments
Trial: 8430049
Drug: Buccal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal delivery of diclofenac sodium from a prototype hydrogel
Trial: 8430049
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) infusion of diclofenac sodium
Trial: 29447248
Drug: Supported park
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supported park prescription (physician counseling, maps, journal, pedometer, phone and text reminders, three weekly family nature outings with free transportation, food, and programming)
Trial: 29447248
Drug: Independent park
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independent park prescription (physician counseling, maps, journal, pedometer)
Trial: 19910619
Drug: Pregabalin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (300 mg before TKA and 150-50 mg twice daily for 14 days after TKA)
Trial: 18303706
Drug: CR plus
RxNorm normalized name: Amino Acids/Chromium Oral Tablet [CR PLUS PROTEIN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR plus nicotine patch (21 mg, CR+NRT) for 16 weeks
Trial: 12004315
Drug: 308-nm xenon-chloride
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 308-nm xenon-chloride excimer laser, treated 3 times a week for a maximum of 12 treatments
Trial: 10207634
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg of aspirin per day for 3 months
Trial: 10207634
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet for 3 months (washout period)
Trial: 7829623
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms iodide plus 100 micrograms L‐T4/day
Trial: 2199628
Drug: Aztreonam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam (2 g i.m.)
Trial: 2199628
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 ml lidocaine 2%)
Trial: 23051740
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blocker (ARB) plus calcium channel blocker (CCB) combination
Trial: 17893454
Drug: Fiberoptic intubation
RxNorm normalized name: ADAPTER,INTUBATION CAREFUSION #1820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiberoptic intubation with a flexible silicone tube without neuromuscular blocking agents
Trial: 17893454
Drug: Orotracheal intubation
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orotracheal intubation with a polyvinyl chloride tube after induction with neuromuscular blocking agents
Trial: 10329078
Drug: Dalteparin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (low molecular weight heparin)
Trial: 6803977
Drug: Chlorpromazine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (1 mg/kg or 4 mg/kg either by mouth or intramuscularly)
Trial: 23462262
Drug: Cefazolin 4
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin 4 g before skin incision and 2 g during skin closure
Trial: 22039966
Drug: Daily multivitamin
RxNorm normalized name: DAILY MULTIVITAMIN TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multivitamin supplement
Trial: 18270356
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (second- and third-line programs)
Trial: 10671850
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac 10 mg made up to 2 ml with saline
Trial: 1490503
Drug: Conventional Madopar
RxNorm normalized name: Madopar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Madopar capsules
Trial: 27021606
Drug: MPH ERCT
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MPH ERCT 40 mg
Trial: 27021606
Drug: IR MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IR MPH 40 mg
Trial: 19952781
Drug: Riboflavin 1.6
RxNorm normalized name: riboflavin 1.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin 1.6 mg per day for 16 weeks
Trial: 18782344
Drug: Aripiprazole (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (up to 15 mg)
Trial: 12745487
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment and nicotine replacement therapy (gum, patch, or inhaler) to reduce smoking by 50% over 4 weeks
Trial: 11910264
Drug: 5-HTP 100
RxNorm normalized name: CVS 5-HTP 100mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HTP 100 mg with carbidopa 100 mg and 50 mg
Trial: 11910264
Drug: 5-HTP 100
RxNorm normalized name: CVS 5-HTP 100mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HTP 100 mg
Trial: 7488373
Drug: Ciprofloxacin hydrochloride
RxNorm normalized name: Ciprofloxacin Hydrochloride
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin hydrochloride (200 mg/mL), 24 patients
Trial: 7488373
Drug: Gentamicin sulfate
RxNorm normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin sulfate (5 mg/mL), 20 patients
Trial: 7036816
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir at 750 mg/m2 body surface area per day for 7 days
Trial: 12185774
Drug: Specialist nursing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specialist nursing intervention; details on dosage and duration not available.
Trial: 9526211
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg enoxaparin subcutaneously once per day
Trial: 9526211
Drug: 5,000 IU
RxNorm normalized name: bleopmycin 15,000 IU Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 IU heparin sodium subcutaneously 3 times daily (increased to 7,500 IU if PTT did not reach 40 seconds)
Trial: 26567123
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment for type 2 diabetes
Trial: 26567123
Drug: Dipeptidyl peptidase‐4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipeptidyl peptidase‐4 inhibitors
Trial: 26391130
Drug: Soluble intercellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble intercellular adhesion molecule-1 (quartiles 2-4)
Trial: 26391130
Drug: Soluble intercellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble intercellular adhesion molecule-1 (multivariable adjustment)
Trial: 23070939
Drug: Buffered solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered solution with mild alkalinity (pH 7.2-7.4)
Trial: 23070939
Drug: Buffered solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered solution with alkalinity (pH 8.2-8.4)
Trial: 23070939
Drug: Nonbuffered solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonbuffered solution (pH 6.2-6.4)
Trial: 15161116
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate injection
Trial: 16614408
Drug: (n‐3) fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (n‐3) fatty acids supplementation (3.6 g (n‐3) fatty acids/d)
Trial: 12574881
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g ceftriaxone i.v. 30 min preoperatively
Trial: 10566718
Drug: No study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study medication (control)
Trial: 24621069
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of a proprietary mixture of non-starch polysaccharides (NSPs) (Ambrotose® complex)
Trial: 12050835
Drug: Ice therapy
RxNorm normalized name: Ice Therapy
DrugBank: Levomenthol (DB00825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ice therapy before chest tube removal
Trial: 7575134
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) inhalation, 800 micrograms/day, twice daily (group A)
Trial: 7575134
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) inhalation, 800 micrograms/day, four times daily (group B)
Trial: 1720012
Drug: Clodronate (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (600 mg iv as a single dose infused over several hours)
Trial: 1720012
Drug: Clodronate (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (oral administration, longer-term effects)
Trial: 7020779
Drug: No-treatment Control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment Control (C)
Trial: 25106731
Drug: FOLFIRI (5-fluorouracil/leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI (5-fluorouracil/leucovorin with irinotecan) in patients who received prior chemotherapy containing oxaliplatin
Trial: 25106731
Drug: IRIS (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRIS (irinotecan plus S-1) in patients who received prior chemotherapy containing oxaliplatin
Trial: 12646120
Drug: Modified extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified extract of Parietaria judaica pollen (depigmented and glutaraldehyde‐polymerized), treatment schedule: incremental phase of 5 injections and maintenance dosage of 0.5 ml per month, total of 14 injections over 12 months
Trial: 12646120
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no specific immunotherapy)
Trial: 10771448
Drug: Ziprasidone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 10 mg day(-1)
Trial: 10771448
Drug: Ziprasidone 40
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40 mg day(-1)
Trial: 10771448
Drug: Ziprasidone 40-80
RxNorm normalized name: ziprasidone 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40-80 mg day(-1)
Trial: 10771448
Drug: Ziprasidone 40-120
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40-120 mg day(-1)
Trial: 10771448
Drug: Ziprasidone (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (various doses)
Trial: 8834415
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg haloperidol with nefazodone
Trial: 1731545
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of 0.9% saline
Trial: 1731545
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of 0.5% (5 mg) lidocaine
Trial: 1731545
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of 1% (10 mg) lidocaine
Trial: 1731545
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of 2% (20 mg) lidocaine
Trial: 6439286
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg twice daily for four weeks
Trial: 6439286
Drug: Naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 250 mg twice daily for four weeks
Trial: 6439286
Drug: Sulindac 200
RxNorm normalized name: sulindac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac 200 mg twice daily for four weeks
Trial: 6439286
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg a day (diuretic treatment)
Trial: 30625023
Drug: Financial Counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Financial Counseling (FC) intervention including education, financial assistance screening, and an estimation tool for out-of-pocket costs of chemotherapy.
Trial: 23017609
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with music therapy
Trial: 8995042
Drug: Spouse-aided treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spouse-aided treatment
Trial: 8995042
Drug: Individual behavioral-cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual behavioral-cognitive therapy
Trial: 31005945
Drug: Workshop and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Workshop and weekly reminders (WR)
Trial: 29239682
Drug: Trivalent seasonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent seasonal influenza vaccine (15 μg of hemagglutinin per strain)
Trial: 25197826
Drug: Brief alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief alcohol intervention (6 counseling sessions approximately monthly)
Trial: 22793966
Drug: Midazolam (0.5mg.kg(‐1))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5mg.kg(‐1)) in 5 mL fruit juice
Trial: 20460227
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (Low dose: 85 mg/d)
Trial: 20460227
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (Medium dose: 230 mg/d)
Trial: 20460227
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (High dose: 500 mg/d)
Trial: 15893155
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg HYD/500 mg ACET
Trial: 15893155
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg HYD/500 mg ACET
Trial: 15893155
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg HYD/1000 mg ACET
Trial: 15893155
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg morphine sulfate (MOR)
Trial: 15893155
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg ACET
Trial: 12739903
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation treatment
Trial: 2563735
Drug: Euglycemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemic clamp protocol (plasma glucose approximately 5.6 mmol/L) for 4 h
Trial: 2563735
Drug: Hyperglycemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemic clamp protocol (plasma glucose about 11 mmol/L) for 4 h
Trial: 25300574
Drug: Oral ginger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ginger
Trial: 19349870
Drug: Lopinavir-ritonavir monotherapy
RxNorm normalized name: lopinavir / ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir-ritonavir monotherapy
Trial: 18097218
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (lopinavir-ritonavir and two nucleosides)
Trial: 9368551
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (t-PA)
Trial: 15619390
Drug: Chlorthalidone (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (12.5 to 25.0 mg/day)
Trial: 15619390
Drug: Diuretic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic therapy (subjects who developed diabetes during treatment)
Trial: 7749698
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of adrenaline (1:10,000) followed by heater probe thermocoagulation
Trial: 7749698
Drug: No endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endoscopic treatment
Trial: 1921531
Drug: Protocol for
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol for characterizing drug-related problems
Trial: 30003839
Drug: Brief guided
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief guided cognitive behavioral treatment (CBT) for perfectionism delivered via a self-help booklet
Trial: 27477473
Drug: Cervicothoracic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervicothoracic manual therapy plus exercise therapy
Trial: 22340428
Drug: JNJ-38431055 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-38431055 (100 mg single-dose)
Trial: 22340428
Drug: JNJ-38431055 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-38431055 (500 mg single-dose)
Trial: 22340428
Drug: JNJ-38431055 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-38431055 (500 mg once daily for 14 days)
Trial: 22340428
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg single-dose)